Biologics Contract Manufacturing Market: Introduction
According to the report, the global biologics contract manufacturing market was valued at US$ 13.3 Bn in 2020 and is projected to expand at a CAGR of 12.2% from 2021 to 2031. Biologics is the application of biotechnology to medicine. These are mostly produced from cell lines and are portentous molecules. Biologics are used in the treatment, diagnosis, or prevention of diseases such as cancer and diabetes. Biologics are manufactured in a living system such as plant cell, animal cell, or microorganisms. These are complex molecules and produced by recombinant technology. Biologics include proteins such as hormones, vaccines, monoclonal antibodies, etc. The global biologics contract manufacturing market is driven by increase in investment in research & development activities and rise in prevalence of chronic diseases.
Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78042
Growth of Biopharmaceutical Industry and Promising Drug Pipeline
Increase in biopharmaceutical sales and promising drug pipeline drive the overall need of biologics clinical development and manufacturing services across the whole spectrum, from pre-clinical services to commercial manufacturing. Over 3,500 recombinant proteins and antibodies are in pre-clinical and clinical trials, including treatments that have been approved. An increasing number of molecules are being developed by small and virtual biotech companies. These companies do not have the in-house manufacturing capacity and expertise to bring their candidates to market, and therefore have a higher propensity to outsource. Presently, these emerging biopharma companies constitute around 80% of the development pipeline.
Request COVID Analysis on Biologics Contract Manufacturing Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78042
Increase in Adoption of Monoclonal Antibodies
In terms of type, the global biologics contract manufacturing market has been classified into monoclonal antibodies, recombinant proteins, vaccines, molecular therapy and others (RNAi, antisense RNA, etc.). The monoclonal antibodies segment was valued at US$ 5.6 Bn in 2020 and is projected to reach US$ 18.9 Bn by 2031, expanding at a CAGR of 11.7% from 2021 to 2031. The segment’s dominance can be attributed to increase in adoption of monoclonal antibodies for large unmet medical needs in the fields of oncology and autoimmune disorders.
North America to Lead Biologics Contract Manufacturing Market
In terms of region, the global biologics contract manufacturing market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The biologics contract manufacturing market in North America was valued at US$ 5.8 Mn in 2020 and is projected to reach US$ 19.5 Bn by 2031, expanding at a CAGR of 11.7 % from 2021 to 2031. The pharmaceutical industry in North America has long been a significant player in the global market for new biologics. Anticancer drugs, as well as enhanced immune class drugs, have been at the forefront of the region’s biopharmaceutical product development, including cutting-edge technologies such as checkpoint inhibitors (e.g. PD1), chimeric antigen receptor (CAR)-T-cell therapies, antibody drug conjugates (ADCs), and monoclonal antibodies (mAbs).
Request Customization on Biologics Contract Manufacturing Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78042
Competition Landscape
The global biologics contract manufacturing market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Lonza Group, Samsung Biologics Co., Ltd., Patheon by Thermo Fisher Scientific, Inc., Cambrex Corporation, Siegfried Holding AG, Fujifilm Holding Corporation, AbbVie, Inc., Boehringer Ingelheim, Recipharm Pharmaceuticals, Catalent, Inc., and Wuxi Biologics.
Buy Biologics Contract Manufacturing Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=78042<ype=S
Global Biologics Contract Manufacturing Market: Segmentation
· Biologics Contract Manufacturing Market, by Type
o Monoclonal Antibodies
o Recombinant Proteins
o Vaccines
o Molecular Therapy
o Others (RNAi, Antisense RNA, etc.)
· Biologics Contract Manufacturing Market, by Region
o North America
§ U.S.
§ Canada
o Europe
§ Germany
§ U.K.
§ France
§ Italy
§ Spain
§ Rest of Europe
o Asia Pacific
§ China
§ India
§ Japan
§ Australia & New Zealand
§ Rest of Asia Pacific
o Latin America
§ Brazil
§ Mexico
§ Rest of Latin America
o Middle East & Africa
§ GCC Countries
§ South Africa
§ Rest of Middle East & Africa
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com/
